Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review
Pancreatic cancer is a rising cause of cancer death. Therapeutic options are scarce and of limited efficacy. Up to 26% of patients with metastatic pancreatic cancer could benefit from targeted therapies. We report here for the first time the case of three patients with metastatic pancreatic ductal a...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241312078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388349412868096 |
|---|---|
| author | Timothée Vigié Alexandre Perrier Brice Chanez Julien De Martino Loëtitia Favre Florence Coulet Jean-Baptiste Bachet Erell Guillerm Léo Mas |
| author_facet | Timothée Vigié Alexandre Perrier Brice Chanez Julien De Martino Loëtitia Favre Florence Coulet Jean-Baptiste Bachet Erell Guillerm Léo Mas |
| author_sort | Timothée Vigié |
| collection | DOAJ |
| description | Pancreatic cancer is a rising cause of cancer death. Therapeutic options are scarce and of limited efficacy. Up to 26% of patients with metastatic pancreatic cancer could benefit from targeted therapies. We report here for the first time the case of three patients with metastatic pancreatic ductal adenocarcinoma (PDAC) without KRAS alteration for whom an activating mutation in exon 19 of the epidermal growth factor receptor ( EGFR ) gene was found through mainstreaming NGS. The EGFR variant was confirmed on multiple tumor samples and by circulating tumor DNA (ctDNA) analysis in two patients. The three patients were treated with osimertinib with early molecular, biologic, and morpho-metabolic responses. At the last follow-up, one patient had an ongoing response after 17 months, and disease control had been maintained for 8 and 6 months in the other two. Known resistance mechanisms were observed on ctDNA analysis at progression. These observations demonstrate the benefit of osimertinib for treating EGFR -mutated PDAC and highlight the interest in investigating rare molecular alterations, especially in patients without KRAS alterations. |
| format | Article |
| id | doaj-art-5c3423ccf27a4ac4a9242f0c7fa4e5f8 |
| institution | Kabale University |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-5c3423ccf27a4ac4a9242f0c7fa4e5f82025-08-20T03:42:19ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-03-011710.1177/17588359241312078Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature reviewTimothée VigiéAlexandre PerrierBrice ChanezJulien De MartinoLoëtitia FavreFlorence CouletJean-Baptiste BachetErell GuillermLéo MasPancreatic cancer is a rising cause of cancer death. Therapeutic options are scarce and of limited efficacy. Up to 26% of patients with metastatic pancreatic cancer could benefit from targeted therapies. We report here for the first time the case of three patients with metastatic pancreatic ductal adenocarcinoma (PDAC) without KRAS alteration for whom an activating mutation in exon 19 of the epidermal growth factor receptor ( EGFR ) gene was found through mainstreaming NGS. The EGFR variant was confirmed on multiple tumor samples and by circulating tumor DNA (ctDNA) analysis in two patients. The three patients were treated with osimertinib with early molecular, biologic, and morpho-metabolic responses. At the last follow-up, one patient had an ongoing response after 17 months, and disease control had been maintained for 8 and 6 months in the other two. Known resistance mechanisms were observed on ctDNA analysis at progression. These observations demonstrate the benefit of osimertinib for treating EGFR -mutated PDAC and highlight the interest in investigating rare molecular alterations, especially in patients without KRAS alterations.https://doi.org/10.1177/17588359241312078 |
| spellingShingle | Timothée Vigié Alexandre Perrier Brice Chanez Julien De Martino Loëtitia Favre Florence Coulet Jean-Baptiste Bachet Erell Guillerm Léo Mas Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review Therapeutic Advances in Medical Oncology |
| title | Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review |
| title_full | Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review |
| title_fullStr | Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review |
| title_full_unstemmed | Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review |
| title_short | Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion: a case report and literature review |
| title_sort | prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with exon 19 deletion a case report and literature review |
| url | https://doi.org/10.1177/17588359241312078 |
| work_keys_str_mv | AT timotheevigie prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT alexandreperrier prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT bricechanez prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT juliendemartino prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT loetitiafavre prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT florencecoulet prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT jeanbaptistebachet prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT erellguillerm prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview AT leomas prolongedresponsetoosimertinibinthreepatientswithrefractorymetastaticpancreaticadenocarcinomaswithexon19deletionacasereportandliteraturereview |